![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 29, 2026
The latest findings in brain tumors, breast cancer, kidney cancer, lung cancer, Merkel cell carcinoma, and precision oncology
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
December 19, 2025
Timely updates on research leaders, presentations at medical meetings and more
November 21, 2025
The latest clinical trial findings in follicular lymphoma, prostate cancer, precision medicine, symptom science, and patient -reported outcomes
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
July 10, 2025
A call to champion federally-funded cancer research, a discussion on limited radiation exposure from CT scans, and a TAILORx trial update
June 11, 2025
Dr. Grivas is honored as an international key opinion thought leader who has made outstanding contributions to genitourinary cancer research, clinical practice, leadership, teaching and mentorship, and community outreach
December 23, 2024
Julie Brahmer, Naomi Haas, and Jedd Wolchok offer insights into a complicated issue that pertains to biomarker testing for treatment selection
November 25, 2024
EA5162 is testing a new therapy for certain patients with advanced NSCLC who have developed resistance to other treatments
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments